Dominican Republic
Tuberculosis profile
| High HIV burden |
Population  2013 10 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.59 (0.37–0.86) 5.7 (3.6–8.2)
Mortality (HIV+TB only) 0.36 (0.28–0.46) 3.5 (2.7–4.4)
Prevalence  (includes HIV+TB) 7.6 (4.1–12) 74 (39–118)
Incidence  (includes HIV+TB) 6.2 (5.6–7.1) 60 (54–68)
Incidence (HIV+TB only) 1.6 (1.5–1.8) 16 (14–18)
Case detection, all forms (%) 72 (63–80)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 6.6 (4.1–10) 20 (13–28)
MDR-TB cases among notified pulmonary
TB cases
230 (150–360) 110 (71–150)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 2 732   338
Pulmonary, clinically diagnosed 821   0
Extrapulmonary 559   0
       
Total new and relapse 4 450    
Previously treated, excluding relapses 213    
Total cases notified 4 663    
Among 4 450 new and relapse cases:
147 (3%) cases aged under 15 years; male:female ratio: 2.9
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 60 (2%) 184 (33%) 388
Laboratory-confirmed RR-/MDR-TB cases     105
Patients started on MDR-TB treatment     126
TB/HIV 2013 Number (%)
TB patients with known HIV status 3 289 (71)
HIV-positive TB patients 813 (25)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 288 (35)
HIV-positive TB patients on antiretroviral therapy (ART) 781 (96)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 171  
Treatment success rate (%)
New cases registered in 2012 82
Previously treated cases registered in 2012 64
HIV-positive TB cases, all types, registered in 2012 67
RR-/MDR-TB cases started on second-line treatment in 2011 61
XDR-TB cases started on second-line treatment in 2011 0
Laboratories 2013  
Smear (per 100 000 population) 1.8
Culture (per 5 million population) 6.2
Drug susceptibility testing (per 5 million population) 1.0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 15
% Funded domestically 62%
% Funded internationally 18%
% Unfunded 21%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-03 Data: www.who.int/tb/data